Kornimate/medical-research-clean huggingface dataset:
embc for perinatal depression and anxiety

Conditions: Depression, Postpartum; Anxiety

Summary: depression and anxiety that occur around the time of pregnancy can adversely impact a person's health and well-being, and their child's health and development. fewer than 20% of affected people are adequately treated, often because of under-use of medications. measurement based care (mbc) is a model of care where psychiatric symptoms are routinely tracked and reviewed together by a patient and their doctor to better manage symptoms. it has not been systematically evaluated for perinatal depression and anxiety. the overall objective of this study is to test the feasibility of mbc in this population to inform a future large randomized controlled trial for definitive evaluation. in order to avoid known barriers to mbc, electronic mbc (embc) will be used. with embc, patients can enter their symptoms into their electronic medical records before their appointment so that they can be evaluated by their doctor during the appointment. in this pilot study, the feasibility of recruitment for a future efficacy trial, including feasibility of recruitment, and retention, acceptability and adherence to a trial protocol will be evaluated.

a parallel group randomized controlled trial (rct) will be conducted. eligible and consenting patients with depression and/or anxiety will be randomized in a 1:1 ratio to either the embc condition or a control condition. the study will be stratified by diagnosis (major depressive disorder vs generalized anxiety disorder). 80 patient participants will be recruited from the reproductive life stages (rls) program at women's college hospital. the active treatment phase of the study is 12 weeks. outcomes will be measured online and by phone at 4-, 8-, and 12- weeks post-randomization. following the completion of the study, some participants will be asked to participate in follow-up interviews. rls psychiatrists whose patients participated in the study will participate in a focus group.

Eligibility criteria:
inclusion criteria: 1. age ≥18 2. currently pregnant or mother\* of a live infant 0-12 months of age and living at the same residence \*through natural birth, adoption, surrogacy, including cis women, non-binary and transgender people in all their diversity 3. epds \>12 at enrollment exclusion criteria: 1. active suicidal ideation, substance abuse or dependence 2. current or past mania or psychosis or current major depressive episode with psychosis 4. incapable of consenting to participation 5. unable to read or unable to speak english

Keywords: measurement based care
effectiveness and safety of lidocaine for scleroderma

Conditions: Scleroderma

Summary: scleroderma, or systemic sclerosis, is a chronic connective tissue disease generally classified as one of the autoimmune rheumatic diseases. the disease is characterized by thickening and fibrosis skin, affecting vessels and many organs such as the esophagus, stomach, bowls, lung, heart and kidney. the exact cause or causes of scleroderma are still unknown, but scientists and medical investigators in a wide variety of fields are working hard to make those determinations. it is known that scleroderma involves overproduction of collagen. flickman et al, in 1973 published an article about the role of lidocaine at prolyl-hydroxylase activity decrease, which is an important enzyme of collagen production. until now, there is only a case series showing the improvement of thickening skin (75%) and esophagus symptoms (66%) after intravenous lidocaine 2% during 10 days. so it is necessary a rct to prove these findings.


Eligibility criteria:
inclusion criteria: * scleroderma (diffuse or limited) at less than 5 years of the first symptom exclusion criteria: * overlap with other connective tissue diseases * fibromyalgia * pregnancy * current use of ciclofosfamide ou d-penicillamine

Keywords: scleroderma scleroderma - limited or diffuse types lidocaine effectiveness
multi-dose vitamin d supplementation in preterm infants

Conditions: Vitamin D Deficiency; Preterm Infants

Summary: preterm newborns are born with lower vitamin d stores. although vitamin d supplementation is recommended there is no consensus regarding the adequate dose of supplementation for preterm infants.

vitamin d is a fat-soluble vitamin that is either taken by dietary sources or synthesized upon exposure to sun light. although major function is on bone metabolism, in recent years other effects of vitamin d attracted attention. low neonatal vitamin d levels were reported to be associated with increased risk of respiratory distress syndrome (rds), bronchopulmonary dysplasia (bpd) and sepsis. vitamin d level in the fetus and the newborn is mostly dependent on maternal vitamin d levels. most of the vitamin d is transferred to the fetus during third trimester and as a result preterm newborns especially those with \<32 weeks gestational age are born with lower vitamin d stores. but there is no consensus regarding the adequate dose of vitamin d supplementation for preterm infants. the american academy of pediatrics recommends supplementation of 200-400 iu/d vitamin d for preterm infants. and the european society of pediatric gastroenterology, hepatology and nutrition (espghan) recommends 800-1000 iu/d vitamin d supplementation for preterm infants.

Eligibility criteria:
inclusion criteria: * preterm infants with gestational age 24 to 32 weeks who achieved at least 75% of total nutrition by enteral feedings in postnatal 2 weeks exclusion criteria: * perinatal asphyxia, * major congenital or chromosomal anomalies, * those with no expectation of survival in first 2 weeks * those that total parenteral nutrition was not ceased by the first 2 weeks
efficacy of using interleukin-2 in antiretroviral naïve hiv patients (anrs119)

Conditions: HIV Infections

Summary: interleukin-2 (il-2) increases the number of cd4 cells in hiv-1 infected patients under highly active antiretroviral therapy (haart) with a cd4 cell count over 200/mm3, but its activity in patients without antiretroviral therapy is unknown. this study will test the efficacy and safety of il-2 in naïve patients with a cd4 count between 300 and 500/m3.

il-2 is produced naturally in the body and helps cd4 cells multiply. in earlier studies in hiv-infection, most of the patients with a controlled viral load under antiretroviral therapy and a high level of cd4 cell count (over 200/mm3) who received il-2, experienced an increase of their cd4 cell count superior to what is observed with antiretroviral therapy alone. the efficacy of il-2 when the viral load is high and the patient is not receiving antiretroviral therapy is not known. the purpose of this multicentric national study is to compare the effects of il-2 versus no treatment in hiv naïve patients. one hundred thirty hiv-1-infected patients, with a cd4 count between 300 and 500/mm3, will be randomly assigned to one of two treatment groups : il-2 or no treatment. the group with il-2 will receive a dose of 4.5 million international units by subcutaneous injection twice a day for 5 days (up to a total of 5 cycles, ending at week 96), the first three cycles 8 weeks apart. evaluation will be done at week 96. the primary endpoint is the proportion of patients reaching an absolute cd4 count below 300/mm3 at week 96. secondary endpoints include the occurrence of hiv-related events, drug safety and the evolution of cd4 cells and of hiv rna and hiv dna loads over time.

Eligibility criteria:
inclusion criteria: * adult patients with proven hiv-1-infection * no prior exposition to antiretrovirals * cd4 cell count between 300 and 500/mm3 * signed written inform consent exclusion criteria: * pregnancy

Keywords: hiv infections interleukin-2
low-intensity shockwave therapy for post-radical prostatectomy erectile dysfunction

Conditions: Erectile Dysfunction Following Radical Prostatectomy

Summary: this research study is trying to determine if low-intensity shock wave therapy (liswt) is safe and effective in patients with symptoms of erectile dysfunction (ed) after radical prostatectomy.

participants will be randomized to the active treatment group or the control/placebo group. all patients on active treatment will receive low-intensity shock wave treatment. participants assigned to the control group will receive the treatment using a sham applicator. the placebo group will receive the same treatment as the active group, but the transducer used for shock wave treatment will be capped, meaning that no shock waves will be transmitted to the penis. participants on active shock wave treatment will receive once a week low-intensity shock wave treatments of 0.2 mj/ mm² over the lateral penile shaft (distal, mid, and proximal penile shaft), 500 impulses in each area, for a total of 1500 shocks along the penis once a week for six weeks, with a total of 6 treatments once a week.

Eligibility criteria:
inclusion criteria: 1. men age 45-70 who had robotic prostatectomy within 6 to 18 months 2. documented nerve sparing during radical prostatectomy procedure 3. mild to moderate ed after prostatectomy 4. iief score \> 18 before surgery 5. testosterone level \> 300 mg/dl post-surgery 6. sexually active exclusion criteria: 1. prior penile surgery 2. lesions or active infections on the penis or perineum 3. anatomical abnormalities in the genitalia or pelvic region 4. unwilling to remove piercing from genital region 5. post radical prostatectomy complications that could impact safety or effectiveness of eswt (hematoma, unresolved anastomotic leak) 6. previous or scheduled treatment with pelvic radiotherapy and/or androgen deprivation therapy 7. anticoagulant medication (except acetylsalicylic acid up to 80 mg daily). 8. any other condition that would prevent the patient from completing the study, as judged by the pi
antiretroviral improvement among medicaid enrollees

Conditions: Human Immunodeficiency Virus

Summary: this study will evaluate whether a new program will affect how often human immunodeficiency virus (hiv) antiretroviral therapy (art) prescriptions are filled and whether the program improves the health of people living with hiv.

virginia commonwealth university and study collaborators are working together to learn about challenges that virginia medicaid members have in taking their prescribed medication. to do this, the researchers are implementing and evaluating a program called antiretroviral improvement among medicaid enrollees (aims). this program is designed to support members to fill art prescriptions. the program involves supporting medicaid members with hiv directly by talking to them about challenges with filling their art prescriptions and linking them to resources that can help with those challenges. some members will be offered access to warm health technology support. the researchers think this support may increase how often art prescriptions are filled and hope that the aims program can improve individuals' health and increase hiv viral suppression.

Eligibility criteria:
inclusion criteria: * current enrollment in virginia medicaid; * continuous virginia medicaid enrollment for the preceding 9 or more months; * current age 19-64 years; * identified as living with hiv according to an hiv case identification algorithm; * non-dual eligible for medicare; * history of art prescription claim(s) within the past 12 months; * prior art prescription claim, with claims for the most recent art prescription refill(s) \>30 days late. exclusion criteria: * record of non-medicaid health insurance or other health care service payer in past 3 months; * new prescription claim(s) within 30 days for within-class art drug(s) not previously prescribed; * service claim(s) for resistance testing and other art prescription claim(s) within 30 days of most recent late art prescription(s) for art drug(s) not previously prescribed; * enrollee's linked hiv provider practices at a healthcare facility offering positivelinks; * no record in the virginia hiv surveillance data; * non-english speaking.
open label phase 1 dose finding study of trc105 in patients with solid cancer

Conditions: Cancer; Neoplasm Metastasis

Summary: this study is being performed to evaluate the safety and tolerability of the trc105 monoclonal antibody.

in addition to safety, this study will also evaluate pharmacokinetics, tumor response and anti-trc105 antibody formation.

Eligibility criteria:
inclusion criteria: * the patient has given informed consent. * the patient is willing and able to abide by the protocol. * the patient has cancer and curative therapy is unavailable. * the patient is at least 18 years old. * the patient has adequate ability to perform activities of daily living. * significant toxicities from prior therapy must have recovered. * the patient has adequate organ function as assessed by laboratory test. exclusion criteria: * the patient weighs more than 264 lbs. * the patient has a known allergy to gentamicin * the patient has had prior treatment with high-dose chemotherapy requiring stem cell rescue * the patient is currently on treatment on another therapeutic clinical trial or has received an investigational agent within 4 weeks prior to first dose with study drug * the patient has had prior surgery (including open biopsy), radiation therapy or systemic therapy within 4 weeks of starting the study treatment * the patient has hypertension \> 160/90 * the patient has a history of cns cancer * the patient has an unstable medical condition including, but not limited to, cardiac disease, history of stroke, active hepatitis, or significant pericardial, pleural or peritoneal effusion * the patient received recent thrombolytic or anticoagulant therapy * the patient has lung cancer with central chest lesions * the patient has had hemorrhage or unhealed wounds within 30 days of dosing * the patient has used systemic corticosteroids within 3 months of dosing * the patient has known hiv/aids * the patient has a history of hypersensitivity reaction to human or mouse antibody products * the patient is pregnant or breastfeeding. * the patient has a history of peptic ulcer disease or gastritis within 6 months of dosing, unless complete resolution has been documented by esophagogastroduodenoscopy (egd) within 30 days of dosing

Keywords: tracon cd105 anti cd105 trc105 phase 1 cancer monoclonal antibody solid tumor
a national registry for patients with hidradenitis suppurativa

Conditions: Hidradenitis Suppurativa

Summary: the goal of this study is to get a better understanding of the skin condition, hidradenitis suppurativa, and to find out how the disease affects quality of life. the investigators hope this information will help improve treatment for this skin condition.

the goal of this study is to get a better understanding of the skin condition, hidradenitis suppurativa, and to find out how the disease affects quality of life. the investigators will utilize a compilation of validated questionnaires including the beck depression inventory form, dermatology life quality index (dlqi), skindex, sf-36 health survey, the quality of life enjoyment and satisfaction questionnaire- short form (q-les-q-sf) and the employment/productivity health economic questionnaire as well as other relevant clinical data. the investigators will additionally collect a modified hidradenitis suppurativa lesion, area, and severity index (hs-lasi) (or other appropriate disease severity score as determined by the team) from the physician of each enrollee. the investigators hope this information will help improve treatment for this skin condition.

Eligibility criteria:
inclusion criteria: * subjects 18-99 years of age who have a diagnosis of hidradenitis suppurativa (as deemed by a physician at the montefiore hidradenitis suppurativa treatment center) exclusion criteria: * patients without a diagnosis of hidradenitis suppurativa or under the age of 18 * patients who are unable to answer given questions within the 6 surveys * patient who are unable to be clinically evaluated by a montefiore physician

Keywords: hidradenitis suppurativa registry
reduction of drug use and hiv risk among out-of-treatment methamphetamine users

Conditions: HIV Infections

Summary: there is a need to identify and test effective strategies to reduce meth use and human immunodeficiency virus (hiv) risk behaviors in heterosexuals. this project will compare the efficacy of a manually-driven hiv testing and counseling (hiv t/c) intervention, with hiv t/c plus a manualized contingency management (cm), with hiv t/c plus cm plus a manualized strengths-based case management (cm/sbcm) model. as hiv t/c is the standard of care, the investigators are testing to determine if the investigators can enhance this standard. the specific aims and hypotheses of this protocol are: 1. to compare the relative efficacy of hiv t/c vs. cm vs. cm/sbcm on reducing drug use, specifically meth use. hypothesis 1: cm/sbcm will reduce drug use more than those in cm (which will have more reduction than hiv t/c), potentially mediated through increased service utilization. 2. to compare the relative efficacy of hiv t/c vs. cm vs. cm/sbcm on reducing hiv and sti risk behaviors, specifically sex risk behaviors but also needle risk for injection drug users (idus). hypothesis 2: cm/sbcm will have greater decreases in hiv risk behaviors than those in cm (which will have greater decreases than hiv t/c), potentially mediated through reduced drug use. 3. to compare the relative efficacy of hiv t/c vs. cm vs. cm/sbcm on improving mental health status. hypothesis 3: cm/sbcm will have greater improvements in mental health status than those in cm (which will have greater improvements than hiv t/c), potentially mediated through increased service utilization and reduction of drug use, and potentially moderated by baseline meth use.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * be competent (not too intoxicated or mentally disabled) to give informed consent at the time of the interview * meth use (verified through urine drug screening and a self-report of meth use of at least 4 times per month for the last 3 months) * self-reported sex with someone of the opposite sex in last 30 days * ability to provide a reliable address and phone number for contact * not in drug treatment in the past 30 days * willingness to be tested for hiv at baseline and follow-up * not transient and no know reason why he/she will not be available for follow-up interviews * not currently mandated by the criminal justice system to receive treatment based on self-report. exclusion criteria: * participation in drug treatment in the past 30 days * currently participating in another project safe study * pregnant or attempting to become pregnant * intoxicated or impaired mentally to the point that they cannot voluntarily consent to participate tin the project and/or respond to the interview

Keywords: hiv infections treatment methamphetamine
living-related donor bone marrow immunoregulation in kidney transplants

Conditions: Kidney Disease

Summary: diabetes and end-stage kidney, liver and heart disease are prominent health issues among veteran patients. successful solid organ transplantation in the absence of chronic immunosuppressive therapy (specific acquired immunological tolerance) is a desirable therapeutic option. this project extends recent observations supporting the use of concommitant donor bone marrow cell infusion as a means of modulating the immune response in kidney transplantation, thereby allowing a substantial decrease or withdrawal of potentially toxic immunosuppressive drugs.


Eligibility criteria:
living related donor kidney transplant recipients and the living related donors.

Keywords: kidney transplantation immunosuppression bone marrow
an open-label extension study to evaluate the safety and tolerability of licarbazepine 750-2000 mg/d in the treatment of manic episodes of bipolar i disorder

Conditions: Bipolar I Disorder

Summary: this extension study is designed to investigate the long-term safety and tolerability of licarbazepine 750-2000 mg/d over 52 weeks in patients who completed the 6-week double-blind study clic477d2302.


Eligibility criteria:
inclusion criteria: * written informed consent provided prior to participation in the extension study. * successful completion of the study clic477d2302 * willingness and ability to comply with all study requirements exclusion criteria: * premature discontinuation from the study clic477d2302 * failure to comply with the study clic477d2302 protocol

Keywords: bipolar i disorder
impact of the crrt management protocol on prognostic outcome in patients with septic acute kidney injury

Conditions: To Explore the Influence of CRRT Nursing Team Management Plan on the Prognosis of SAKI Patients

Summary: the implementation of crrt nursing team management program in the treatment of saki can significantly reduce the incidence of adverse events and complications in crrt nursing, which has a positive role in improving the success rate of crrt treatment and the clinical outcome of patients.


Eligibility criteria:
inclusion criteria: * the guidelines for emergency treatment of sepsis / septic shock in china (2018)\[4\]diagnostic criteria for moderate sepsis; ② meets the organization for improving global kidney disease outcomes (kdigo) clinical practice guidelines: aki\[5\]relevant diagnostic criteria in; ③ received crrt as indicated for crrt; ④ in icu for longer than 24 hours; ⑤ signed consent. exclusion criteria: * with chronic organ failure, or advanced malignancy; ② with previous history of chronic kidney disease, retrorenal urinary tract obstruction; ③ with incomplete clinical data.
multi-disciplinary treatment on the anthropomorphism of large language models

Conditions: Cancer; Respiratory Failure; Heart Diseases; Infections; Pneumonia; Disease

Summary: this retrospective clinical trial aims to better explore the potential of large language models in medicine by comparing the effectiveness of mdt consultations conducted by human doctors with those conducted by large language models. the main questions to be addressed are: does using large language models to conduct anthropomorphic mdt consultations yield better results than using non-anthropomorphic processes? is there a significant performance gap between mdt consultations conducted by large language models and those conducted by humans? how much greater is the economic benefit of mdt consultations from large language models compared to those conducted by humans? retrospectively collect mdt consultation records from the past 20 years in northern sichuan in china, as well as anonymized patient medical records. group 1: different large language models are assigned to act as doctors from different departments and as mdt secretaries to summarize consultations. group 2: the large language model directly outputs diagnostic and treatment recommendations for patients. compare the outputs of groups 1 and 2 with human performance retrospectively, score them, and select the best model from each department for a re-evaluation through anthropomorphic mdt consultations, once again comparing them to human results.


Eligibility criteria:
inclusion criteria: * 1. the medical records include interdisciplinary consultation notes, with recommendations from specialists of various departments and a well-documented final summary. * 2. the medical records contain data from at least one year prior to and one year following the consultation (including intact reports and imaging records). * 3. the patient\&amp;#39;s discharge conditions improved due to the multidisciplinary treatment plan after the consultation. exclusion criteria: * 1. the medical records do not include multidisciplinary consultation notes, or the recommendations from various departmental physicians and the final summary notes are incomplete or inadequate. * 2. the medical records lack data from 1 year before and after the consultation, or miss necessary reports and imaging data, resulting in incomplete documentation. * 3. the patient\&amp;#39;s condition at discharge has not improved following the multidisciplinary treatment plan, or the condition has worsened.